Risk of Cardiovascular Disease in Patients With Classical Hodgkin Lymphoma: A Danish Nationwide Register‐Based Cohort Study

Figures

• 

  FIGURE 1. Flowchart summarizing the inclusion, exclusion, and final study population size. ABVD: doxorubicin‐bleomycin‐vinblastine‐dacarbazine; BEACOPP: bleomycin‐etoposide‐doxorubicin‐cyclophosphamide‐vincristine‐procarbazine‐predinisolone; CPR: civil personal registration.

• 

  FIGURE 2. Cause specific cumulative incidence curve and number at risk of the primary endpoint for classical Hodgkin lymphoma patients and matched comparators. HL: classical Hodgkin lymphoma.

• 

  FIGURE 3. Stacked cumulative incidences at 5‐, 10‐, and 15‐years of the secondary endpoints for patients with HL and comparators. Please note that each cumulative incidence is based on first event of that diagnosis meaning that an individual can appear in multiple categories. HL: classical Hodgkin lymphoma.

• 

  FIGURE 4. Hazard ratios of the primary outcome in patients with classical Hodgkin lymphoma comparing different clinicopathological features. ECOG: eastern cooperative oncology group performance status; HR: hazard ratio.